Sangamo Shares Surge 29% on FDA Rolling BLA Acceptance for Fabry Gene Therapy

Introduction

Sangamo Therapeutics, Inc. (Nasdaq: SGMO) is a biotechnology research company headquartered in Brisbane, California. Founded in 1995, Sangamo applies proprietary zinc finger and gene-editing technologies to develop treatments for severe genetic diseases. Its pipeline includes programs targeting Fabry disease, hemophilia, neurodegenerative disorders, and prion disease.

Corporate Structure and Experience

According to LinkedIn, Sangamo employs between 201 and 500 staff globally. Leadership includes President and CEO Sandy Macrae, who has overseen the expansion of the company’s genomic medicine platforms. Sangamo’s operations encompass research, clinical development, and manufacturing activities, supported by collaborations with major pharmaceutical partners.

Gene therapy by Sangharsh Lohakare

Developments and News

• On November 6, 2025, Sangamo filed its Form 10-Q for the quarter ended September 30, 2025, reporting revenue of $32.9 million and a net loss of $108.9 million. The company held $29.6 million in cash and cash equivalents and had a debt-to-equity ratio of 4.07.
• On November 12, 2025, an amendment to a Schedule 13G filing revealed that Wasatch Advisors LP held 6,188,358 shares (2.1%) of Sangamo’s common stock, with sole voting power over 5,587,777 shares.
• On November 19, 2025, the U.S. Food and Drug Administration accepted Sangamo’s request for a rolling Biologics License Application review of ST-920, its gene therapy candidate for Fabry disease. In meeting minutes, the FDA confirmed the use of estimated glomerular filtration rate (eGFR) slope as an accelerated approval endpoint.
• In October 2025, the Nobel Prize in Physiology or Medicine was awarded to Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi for research on regulatory T cells. Sangamo noted its involvement in the first dosing of engineered CAR-T regulatory cells (TX200) in kidney transplantation studies.
• During the third quarter of 2025, Sangamo presented preclinical data for ST-506, an AAV-based zinc finger repressor therapy for prion disease. Studies in nonhuman primates demonstrated widespread brain delivery and sustained target gene repression.

Financial and Strategic Analysis

As of November 21, 2025, SGMO shares closed at $0.4972, up 29.14% on a volume of 4,243,353 shares. The 52-week trading range spans from $0.41 to $2.84, and market capitalization is approximately $148 million. Trailing twelve-month metrics from Yahoo Finance show:

• Revenue: $32.9 million
• Net loss: $108.9 million
• Cash and equivalents: $29.6 million
• Total debt/equity: 407%

Sangamo’s continued net losses reflect significant investments in research and development and clinical trial expenses. Collaborations with Pfizer, Genentech, Eli Lilly, and others support the development and commercialization of multiple gene therapies. The debt load indicates reliance on partner milestones and future equity or licensing arrangements to fund operations.

Market Position and Industry Context

Sangamo operates in a competitive gene therapy sector alongside companies developing CRISPR, base editors, and RNA-based treatments. Its proprietary zinc finger platforms and integrase (MINT) technology differentiate it from purely nuclease-based approaches. The company’s market capitalization and early-stage pipeline position it within the speculative segment of the biotechnology industry, subject to clinical, regulatory, and financing risks associated with gene-editing firms.

tl;dr

SGMO rose 29.14% to $0.4972 on November 21, 2025, on a volume of 4.24 million shares. Recent filings included a Schedule 13G/A showing Wasatch Advisors’ 2.1% stake, and a 10-Q reporting $32.9 million in revenue and a $108.9 million net loss over the past year, with $29.6 million in cash. On November 19, 2025, the FDA accepted a rolling BLA for ST-920 in Fabry disease, designating eGFR slope for accelerated approval. Preclinical data for ST-506 support clinical filings. Future funding and trial outcomes will influence Sangamo’s ability to advance its zinc finger-based pipeline.